Vermfugo and asthma medicine can kill the coronavirus in the laboratory



[ad_1]

(photo: Bayer AG / Divulga
(photo: Bayer AG / Divulgao)

South Korean researchers identified two more remedies which showed promising signs against the new coronavirus in laboratory tests. The two drugs were shown to be able to overcome the cause of Covid-19 in laboratory tests on cells.

Both drugs have already been approved in the United States for the treatment of other diseases, which should facilitate their use against Covid-19. However, the results, scientists say, are still preliminary and no human testing has been done. The research was published in Antimicrobial agents and chemotherapy, specialized journal of the American Society for Microbiology.

For the study, the researchers tested 46 drugs (all used to treat other diseases) on Vero cells, a strain developed from the kidney cells of the African green monkey. These cells are commonly used in virus culture for vaccine production.

Vermfugo

One of the drugs is vermifuge niclosamide, which is used to treat leasing. “Not surprisingly, its broad-spectrum antiviral effect has been well documented in the literature, including antiviral properties against SARS (severe acute respiratory syndrome) and MERS-CoV (Middle East respiratory syndrome),” the authors state in a press release.

Despite the positive results, the authors noted that a disadvantage of niclosamide is its low absorption by the body.
The other medication is ciclesonide antiviral, an inhaled corticosteride that is used to treat asthma and allergic rhinitis. “With its proven anti-inflammatory activity, ciclesonide may represent a potent drug that can manifest itself [os] double roles [de antiviral e anti-inflamatrio] in controlling SARS-CoV-2 infection, “the researchers conclude.

Other drugs

North American and Hong Kong researchers have already identified around 30 drugs that are effective against Covid-19. All are candidates for medications to treat the new coronavirus. Three are currently in clinical trials for Covid-19.

[ad_2]